Breast Cancer

Experts explore the clinical promise, nursing implications, and access barriers of GLP-1s in cancer care.

Dr. Sonja J. Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and survivors.

FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer.

The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial.

Dr. Loren Rourke discusses how GLP-1s may impact breast cancer risk by reducing adipose tissue-derived estrogen and chronic metabolic inflammation.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, survival, and immune-related adverse events.

Study findings suggest biologic aging and neighborhood deprivation may shape cognitive benefits from exercise after breast cancer.

The FDA approved T-DXd for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, showing improved pCR and IDFS rates.

Experts warn of "molecular anxiety" and financial toxicity as ctDNA testing enters early-stage breast cancer surveillance.

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects.

FDA approved Veppanu for ER+, HER2- ESR1-mutated breast cancer after endocrine therapy, improving PFS to 5 months vs 2.1 and reducing progression risk by 43%.

Paget disease of the breast: key signs, diagnosis, and treatment strategies oncology nurses should know to support early detection and patient care.

Consistent assessment and follow-up help manage low-grade irAEs, with continued monitoring and coordination supporting long-term toxicity care.

Dr. Don Dizon discusses why early fertility referral and avoiding clinical assumptions are vital for young breast cancer patients at diagnosis.

The OPTIMAL trial shows oral DHP107 matches IV paclitaxel efficacy in HER2-negative metastatic breast cancer with lower rates of neuropathy.

The NCCN has added sacituzumab govitecan with pembrolizumab as a category 1 preferred regimen for patients with PD-L1–postive TNBC.

Radiation-induced heart damage in breast cancer is a growing clinical concern, yet biomarkers and preventive therapies remain lacking.

A multidisciplinary approach to care is key when addressing sexual health concerns among breast cancer survivors.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.